1-20 of 877 results for answeredby:"James Frith"
Librarians' tools
- Search time
- 0.275 seconds
- Solr query time
- 0.003 seconds
- Search query
- answeredby:"James Frith"
- We searched for
- answeringMember_ses:437165 OR answeringDept_ses:437165 OR askedToReplyAuthor_ses:437165
Type
House
Session
Year
Department
Member
More
Primary member
More
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, what steps she is taking to pilot proactive breast cancer risk assessment.
To ask the Secretary of State for Health and Social Care, what steps she is taking to pilot proactive breast cancer risk assessment.
The National Cancer Plan commits to more proactive identification of cancer risk, including through genomic testing and improved case-finding. Eligible patients diagnosed with breast or ovarian cancer will receive testing for relevant genes, including BRCA1 and BRCA2, helping the National Health Service to identify people who may benefit from targeted surveillance and other risk-management measures.
The NHS National Inherited Cancer Predisposition Register will also support targeted prevention, surveillance and earlier diagnosis. Women at very high risk of breast cancer can access the NHS Breast Screening Programme’s very high-risk surveillance pathway.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the long-term health and care needs of people who have suffered traumatic brain injuries in e-vehicle incidents.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the long-term health and care needs of people who have suffered traumatic brain injuries in e-vehicle incidents.
The Department does not centrally hold the requested data, but the National Health Service continues to provide assessment, treatment and rehabilitation for people with all types of traumatic brain injuries according to their individual clinical needs.
More widely, the Government is taking forward a range of measures to improve the safety of e-scooters and e-bikes, including strengthening the regulatory framework for these types of vehicles, and has introduced measures to tackle illegally modified e-bikes, including strengthened product safety and enforcement powers.
To ask the Secretary of State for Health and Social Care, what data her department holds on the number of patients treated for traumatic head injuries following incidents involving e-scooters and e-bikes in each of the last five years.
To ask the Secretary of State for Health and Social Care, what data her department holds on the number of patients treated for traumatic head injuries following incidents involving e-scooters and e-bikes in each of the last five years.
The Department does not centrally hold the requested data, but the National Health Service continues to provide assessment, treatment and rehabilitation for people with all types of traumatic brain injuries according to their individual clinical needs.
More widely, the Government is taking forward a range of measures to improve the safety of e-scooters and e-bikes, including strengthening the regulatory framework for these types of vehicles, and has introduced measures to tackle illegally modified e-bikes, including strengthened product safety and enforcement powers.
To ask the Secretary of State for Health and Social Care, if she will set out the recruitment process for the planned roundtable aimed at boosting participation for brain cancer clinical trials.
To ask the Secretary of State for Health and Social Care, if she will set out the recruitment process for the planned roundtable aimed at boosting participation for brain cancer clinical trials.
The announcements that the Hon. Member is referring to were made on 14 October, with further information available at the link below. We will set out further details in the normal way in due course.
https://www.gov.uk/government/news/brain-cancer-patients-to-see-faster-development-of-new-treatments
To ask the Secretary of State for Health and Social Care, whether she will confirm a timeline for the appointment of the national brain cancer clinical lead.
To ask the Secretary of State for Health and Social Care, whether she will confirm a timeline for the appointment of the national brain cancer clinical lead.
The announcements that the Hon. Member is referring to were made on 14 October, with further information available at the link below. We will set out further details in the normal way in due course.
https://www.gov.uk/government/news/brain-cancer-patients-to-see-faster-development-of-new-treatments
To ask the Secretary of State for Health and Social Care, whether information standards in force under section 250 of the Health and Social Care Act 2012 will be (a) replaced by mandatory information standards made under the amended framework introduced by the Health and Care Act 2022, (b) revoked...
To ask the Secretary of State for Health and Social Care, whether information standards in force under section 250 of the Health and Social Care Act 2012 will be (a) replaced by mandatory information standards made under the amended framework introduced by the Health and Care Act 2022, (b) revoked...
To ask the Secretary of State for Health and Social Care, what measures exist to support patients recovering from stroke.
To ask the Secretary of State for Health and Social Care, what measures exist to support patients recovering from stroke.
The Hon. Member has asked several questions about the diagnosis and treatment of several well-known conditions. For each of these, I refer him below to the most recent comprehensive answer provided in the House on the condition in question, or to the publicly available guidance on the National Health Service website:
on motor neurone disease, I refer him to the answer provided on 7 September in response to Question 22114;
on Crohn’s disease and ulcerative colitis, I refer him to the answer provided on 27 May in response to Question 2655;
on epilepsy, I refer him to the answer provided on 3 June in response to Question 2410;
on cystic fibrosis, I refer him to the answer provided on 23 June 2025 in response to Question 59881;
on psoriasis, the data which the Hon. Member has requested is not centrally held, but I refer him to the NHS guidance, available at the following link: https://www.nhs.uk/conditions/psoriasis/;
on coeliac disease, I refer him to the answer provided on 20 April in response to Question 127290;
on lupus, I refer him to the NHS guidance available at the following link: https://www.nhs.uk/conditions/lupus/;
on Huntington's disease, I refer him to the answer provided on 3 November 2025 in response to Question 78112;
on autism spectrum disorder and attention deficit hyperactivity disorder, I refer him to the answer provided on 16 October in response to Question 33657;
on Parkinson’s disease, I refer him to the answer provided on 17 July in response to Question 18388;
on multiple sclerosis, I refer him to the answer he received on 22 September in response to Question 28315;
on ovarian cancer, I refer him to the answer provided on 28 April in response to Question 129512;
on pancreatic cancer, I refer him to the answer provided on 15 July in response to Question 16704;
on sickle cell disease and thalassemia, I refer him to the answer provided on 24 April 2025 in response to Question 45488; and
on stroke, I refer him to the answer provided on 10 September 2025 in response to Question 71502.
To ask the Secretary of State for Health and Social Care, what steps she is taking to help reduce inequalities in care for those with thalassemia.
To ask the Secretary of State for Health and Social Care, what steps she is taking to help reduce inequalities in care for those with thalassemia.
The Hon. Member has asked several questions about the diagnosis and treatment of several well-known conditions. For each of these, I refer him below to the most recent comprehensive answer provided in the House on the condition in question, or to the publicly available guidance on the National Health Service website:
on motor neurone disease, I refer him to the answer provided on 7 September in response to Question 22114;
on Crohn’s disease and ulcerative colitis, I refer him to the answer provided on 27 May in response to Question 2655;
on epilepsy, I refer him to the answer provided on 3 June in response to Question 2410;
on cystic fibrosis, I refer him to the answer provided on 23 June 2025 in response to Question 59881;
on psoriasis, the data which the Hon. Member has requested is not centrally held, but I refer him to the NHS guidance, available at the following link: https://www.nhs.uk/conditions/psoriasis/;
on coeliac disease, I refer him to the answer provided on 20 April in response to Question 127290;
on lupus, I refer him to the NHS guidance available at the following link: https://www.nhs.uk/conditions/lupus/;
on Huntington's disease, I refer him to the answer provided on 3 November 2025 in response to Question 78112;
on autism spectrum disorder and attention deficit hyperactivity disorder, I refer him to the answer provided on 16 October in response to Question 33657;
on Parkinson’s disease, I refer him to the answer provided on 17 July in response to Question 18388;
on multiple sclerosis, I refer him to the answer he received on 22 September in response to Question 28315;
on ovarian cancer, I refer him to the answer provided on 28 April in response to Question 129512;
on pancreatic cancer, I refer him to the answer provided on 15 July in response to Question 16704;
on sickle cell disease and thalassemia, I refer him to the answer provided on 24 April 2025 in response to Question 45488; and
on stroke, I refer him to the answer provided on 10 September 2025 in response to Question 71502.
To ask the Secretary of State for Health and Social Care, what support exists for individuals with sickle cell disease.
To ask the Secretary of State for Health and Social Care, what support exists for individuals with sickle cell disease.
The Hon. Member has asked several questions about the diagnosis and treatment of several well-known conditions. For each of these, I refer him below to the most recent comprehensive answer provided in the House on the condition in question, or to the publicly available guidance on the National Health Service website:
on motor neurone disease, I refer him to the answer provided on 7 September in response to Question 22114;
on Crohn’s disease and ulcerative colitis, I refer him to the answer provided on 27 May in response to Question 2655;
on epilepsy, I refer him to the answer provided on 3 June in response to Question 2410;
on cystic fibrosis, I refer him to the answer provided on 23 June 2025 in response to Question 59881;
on psoriasis, the data which the Hon. Member has requested is not centrally held, but I refer him to the NHS guidance, available at the following link: https://www.nhs.uk/conditions/psoriasis/;
on coeliac disease, I refer him to the answer provided on 20 April in response to Question 127290;
on lupus, I refer him to the NHS guidance available at the following link: https://www.nhs.uk/conditions/lupus/;
on Huntington's disease, I refer him to the answer provided on 3 November 2025 in response to Question 78112;
on autism spectrum disorder and attention deficit hyperactivity disorder, I refer him to the answer provided on 16 October in response to Question 33657;
on Parkinson’s disease, I refer him to the answer provided on 17 July in response to Question 18388;
on multiple sclerosis, I refer him to the answer he received on 22 September in response to Question 28315;
on ovarian cancer, I refer him to the answer provided on 28 April in response to Question 129512;
on pancreatic cancer, I refer him to the answer provided on 15 July in response to Question 16704;
on sickle cell disease and thalassemia, I refer him to the answer provided on 24 April 2025 in response to Question 45488; and
on stroke, I refer him to the answer provided on 10 September 2025 in response to Question 71502.
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve outcomes for patients with pancreatic cancer.
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve outcomes for patients with pancreatic cancer.
The Hon. Member has asked several questions about the diagnosis and treatment of several well-known conditions. For each of these, I refer him below to the most recent comprehensive answer provided in the House on the condition in question, or to the publicly available guidance on the National Health Service website:
on motor neurone disease, I refer him to the answer provided on 7 September in response to Question 22114;
on Crohn’s disease and ulcerative colitis, I refer him to the answer provided on 27 May in response to Question 2655;
on epilepsy, I refer him to the answer provided on 3 June in response to Question 2410;
on cystic fibrosis, I refer him to the answer provided on 23 June 2025 in response to Question 59881;
on psoriasis, the data which the Hon. Member has requested is not centrally held, but I refer him to the NHS guidance, available at the following link: https://www.nhs.uk/conditions/psoriasis/;
on coeliac disease, I refer him to the answer provided on 20 April in response to Question 127290;
on lupus, I refer him to the NHS guidance available at the following link: https://www.nhs.uk/conditions/lupus/;
on Huntington's disease, I refer him to the answer provided on 3 November 2025 in response to Question 78112;
on autism spectrum disorder and attention deficit hyperactivity disorder, I refer him to the answer provided on 16 October in response to Question 33657;
on Parkinson’s disease, I refer him to the answer provided on 17 July in response to Question 18388;
on multiple sclerosis, I refer him to the answer he received on 22 September in response to Question 28315;
on ovarian cancer, I refer him to the answer provided on 28 April in response to Question 129512;
on pancreatic cancer, I refer him to the answer provided on 15 July in response to Question 16704;
on sickle cell disease and thalassemia, I refer him to the answer provided on 24 April 2025 in response to Question 45488; and
on stroke, I refer him to the answer provided on 10 September 2025 in response to Question 71502.
To ask the Secretary of State for Health and Social Care, how the NHS supports early detection of ovarian cancer.
To ask the Secretary of State for Health and Social Care, how the NHS supports early detection of ovarian cancer.
The Hon. Member has asked several questions about the diagnosis and treatment of several well-known conditions. For each of these, I refer him below to the most recent comprehensive answer provided in the House on the condition in question, or to the publicly available guidance on the National Health Service website:
on motor neurone disease, I refer him to the answer provided on 7 September in response to Question 22114;
on Crohn’s disease and ulcerative colitis, I refer him to the answer provided on 27 May in response to Question 2655;
on epilepsy, I refer him to the answer provided on 3 June in response to Question 2410;
on cystic fibrosis, I refer him to the answer provided on 23 June 2025 in response to Question 59881;
on psoriasis, the data which the Hon. Member has requested is not centrally held, but I refer him to the NHS guidance, available at the following link: https://www.nhs.uk/conditions/psoriasis/;
on coeliac disease, I refer him to the answer provided on 20 April in response to Question 127290;
on lupus, I refer him to the NHS guidance available at the following link: https://www.nhs.uk/conditions/lupus/;
on Huntington's disease, I refer him to the answer provided on 3 November 2025 in response to Question 78112;
on autism spectrum disorder and attention deficit hyperactivity disorder, I refer him to the answer provided on 16 October in response to Question 33657;
on Parkinson’s disease, I refer him to the answer provided on 17 July in response to Question 18388;
on multiple sclerosis, I refer him to the answer he received on 22 September in response to Question 28315;
on ovarian cancer, I refer him to the answer provided on 28 April in response to Question 129512;
on pancreatic cancer, I refer him to the answer provided on 15 July in response to Question 16704;
on sickle cell disease and thalassemia, I refer him to the answer provided on 24 April 2025 in response to Question 45488; and
on stroke, I refer him to the answer provided on 10 September 2025 in response to Question 71502.
To ask the Secretary of State for Health and Social Care, what specialist provision exists for patients with multiple sclerosis.
To ask the Secretary of State for Health and Social Care, what specialist provision exists for patients with multiple sclerosis.
The Hon. Member has asked several questions about the diagnosis and treatment of several well-known conditions. For each of these, I refer him below to the most recent comprehensive answer provided in the House on the condition in question, or to the publicly available guidance on the National Health Service website:
on motor neurone disease, I refer him to the answer provided on 7 September in response to Question 22114;
on Crohn’s disease and ulcerative colitis, I refer him to the answer provided on 27 May in response to Question 2655;
on epilepsy, I refer him to the answer provided on 3 June in response to Question 2410;
on cystic fibrosis, I refer him to the answer provided on 23 June 2025 in response to Question 59881;
on psoriasis, the data which the Hon. Member has requested is not centrally held, but I refer him to the NHS guidance, available at the following link: https://www.nhs.uk/conditions/psoriasis/;
on coeliac disease, I refer him to the answer provided on 20 April in response to Question 127290;
on lupus, I refer him to the NHS guidance available at the following link: https://www.nhs.uk/conditions/lupus/;
on Huntington's disease, I refer him to the answer provided on 3 November 2025 in response to Question 78112;
on autism spectrum disorder and attention deficit hyperactivity disorder, I refer him to the answer provided on 16 October in response to Question 33657;
on Parkinson’s disease, I refer him to the answer provided on 17 July in response to Question 18388;
on multiple sclerosis, I refer him to the answer he received on 22 September in response to Question 28315;
on ovarian cancer, I refer him to the answer provided on 28 April in response to Question 129512;
on pancreatic cancer, I refer him to the answer provided on 15 July in response to Question 16704;
on sickle cell disease and thalassemia, I refer him to the answer provided on 24 April 2025 in response to Question 45488; and
on stroke, I refer him to the answer provided on 10 September 2025 in response to Question 71502.
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve diagnosis of coeliac disease.
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve diagnosis of coeliac disease.
The Hon. Member has asked several questions about the diagnosis and treatment of several well-known conditions. For each of these, I refer him below to the most recent comprehensive answer provided in the House on the condition in question, or to the publicly available guidance on the National Health Service website:
on motor neurone disease, I refer him to the answer provided on 7 September in response to Question 22114;
on Crohn’s disease and ulcerative colitis, I refer him to the answer provided on 27 May in response to Question 2655;
on epilepsy, I refer him to the answer provided on 3 June in response to Question 2410;
on cystic fibrosis, I refer him to the answer provided on 23 June 2025 in response to Question 59881;
on psoriasis, the data which the Hon. Member has requested is not centrally held, but I refer him to the NHS guidance, available at the following link: https://www.nhs.uk/conditions/psoriasis/;
on coeliac disease, I refer him to the answer provided on 20 April in response to Question 127290;
on lupus, I refer him to the NHS guidance available at the following link: https://www.nhs.uk/conditions/lupus/;
on Huntington's disease, I refer him to the answer provided on 3 November 2025 in response to Question 78112;
on autism spectrum disorder and attention deficit hyperactivity disorder, I refer him to the answer provided on 16 October in response to Question 33657;
on Parkinson’s disease, I refer him to the answer provided on 17 July in response to Question 18388;
on multiple sclerosis, I refer him to the answer he received on 22 September in response to Question 28315;
on ovarian cancer, I refer him to the answer provided on 28 April in response to Question 129512;
on pancreatic cancer, I refer him to the answer provided on 15 July in response to Question 16704;
on sickle cell disease and thalassemia, I refer him to the answer provided on 24 April 2025 in response to Question 45488; and
on stroke, I refer him to the answer provided on 10 September 2025 in response to Question 71502.
To ask the Secretary of State for Health and Social Care, what specialist services are available for individuals with lupus.
To ask the Secretary of State for Health and Social Care, what specialist services are available for individuals with lupus.
The Hon. Member has asked several questions about the diagnosis and treatment of several well-known conditions. For each of these, I refer him below to the most recent comprehensive answer provided in the House on the condition in question, or to the publicly available guidance on the National Health Service website:
on motor neurone disease, I refer him to the answer provided on 7 September in response to Question 22114;
on Crohn’s disease and ulcerative colitis, I refer him to the answer provided on 27 May in response to Question 2655;
on epilepsy, I refer him to the answer provided on 3 June in response to Question 2410;
on cystic fibrosis, I refer him to the answer provided on 23 June 2025 in response to Question 59881;
on psoriasis, the data which the Hon. Member has requested is not centrally held, but I refer him to the NHS guidance, available at the following link: https://www.nhs.uk/conditions/psoriasis/;
on coeliac disease, I refer him to the answer provided on 20 April in response to Question 127290;
on lupus, I refer him to the NHS guidance available at the following link: https://www.nhs.uk/conditions/lupus/;
on Huntington's disease, I refer him to the answer provided on 3 November 2025 in response to Question 78112;
on autism spectrum disorder and attention deficit hyperactivity disorder, I refer him to the answer provided on 16 October in response to Question 33657;
on Parkinson’s disease, I refer him to the answer provided on 17 July in response to Question 18388;
on multiple sclerosis, I refer him to the answer he received on 22 September in response to Question 28315;
on ovarian cancer, I refer him to the answer provided on 28 April in response to Question 129512;
on pancreatic cancer, I refer him to the answer provided on 15 July in response to Question 16704;
on sickle cell disease and thalassemia, I refer him to the answer provided on 24 April 2025 in response to Question 45488; and
on stroke, I refer him to the answer provided on 10 September 2025 in response to Question 71502.
To ask the Secretary of State for Health and Social Care, what steps she is taking to support research into Huntington's disease.
To ask the Secretary of State for Health and Social Care, what steps she is taking to support research into Huntington's disease.
The Hon. Member has asked several questions about the diagnosis and treatment of several well-known conditions. For each of these, I refer him below to the most recent comprehensive answer provided in the House on the condition in question, or to the publicly available guidance on the National Health Service website:
on motor neurone disease, I refer him to the answer provided on 7 September in response to Question 22114;
on Crohn’s disease and ulcerative colitis, I refer him to the answer provided on 27 May in response to Question 2655;
on epilepsy, I refer him to the answer provided on 3 June in response to Question 2410;
on cystic fibrosis, I refer him to the answer provided on 23 June 2025 in response to Question 59881;
on psoriasis, the data which the Hon. Member has requested is not centrally held, but I refer him to the NHS guidance, available at the following link: https://www.nhs.uk/conditions/psoriasis/;
on coeliac disease, I refer him to the answer provided on 20 April in response to Question 127290;
on lupus, I refer him to the NHS guidance available at the following link: https://www.nhs.uk/conditions/lupus/;
on Huntington's disease, I refer him to the answer provided on 3 November 2025 in response to Question 78112;
on autism spectrum disorder and attention deficit hyperactivity disorder, I refer him to the answer provided on 16 October in response to Question 33657;
on Parkinson’s disease, I refer him to the answer provided on 17 July in response to Question 18388;
on multiple sclerosis, I refer him to the answer he received on 22 September in response to Question 28315;
on ovarian cancer, I refer him to the answer provided on 28 April in response to Question 129512;
on pancreatic cancer, I refer him to the answer provided on 15 July in response to Question 16704;
on sickle cell disease and thalassemia, I refer him to the answer provided on 24 April 2025 in response to Question 45488; and
on stroke, I refer him to the answer provided on 10 September 2025 in response to Question 71502.
To ask the Secretary of State for Health and Social Care, what progress she has made on improving outcomes for patients with motor neurone disease.
To ask the Secretary of State for Health and Social Care, what progress she has made on improving outcomes for patients with motor neurone disease.
The Hon. Member has asked several questions about the diagnosis and treatment of several well-known conditions. For each of these, I refer him below to the most recent comprehensive answer provided in the House on the condition in question, or to the publicly available guidance on the National Health Service website:
on motor neurone disease, I refer him to the answer provided on 7 September in response to Question 22114;
on Crohn’s disease and ulcerative colitis, I refer him to the answer provided on 27 May in response to Question 2655;
on epilepsy, I refer him to the answer provided on 3 June in response to Question 2410;
on cystic fibrosis, I refer him to the answer provided on 23 June 2025 in response to Question 59881;
on psoriasis, the data which the Hon. Member has requested is not centrally held, but I refer him to the NHS guidance, available at the following link: https://www.nhs.uk/conditions/psoriasis/;
on coeliac disease, I refer him to the answer provided on 20 April in response to Question 127290;
on lupus, I refer him to the NHS guidance available at the following link: https://www.nhs.uk/conditions/lupus/;
on Huntington's disease, I refer him to the answer provided on 3 November 2025 in response to Question 78112;
on autism spectrum disorder and attention deficit hyperactivity disorder, I refer him to the answer provided on 16 October in response to Question 33657;
on Parkinson’s disease, I refer him to the answer provided on 17 July in response to Question 18388;
on multiple sclerosis, I refer him to the answer he received on 22 September in response to Question 28315;
on ovarian cancer, I refer him to the answer provided on 28 April in response to Question 129512;
on pancreatic cancer, I refer him to the answer provided on 15 July in response to Question 16704;
on sickle cell disease and thalassemia, I refer him to the answer provided on 24 April 2025 in response to Question 45488; and
on stroke, I refer him to the answer provided on 10 September 2025 in response to Question 71502.
To ask the Secretary of State for Health and Social Care, what mechanisms are in place to identify and reassess patients previously considered ineligible for hereditary cancer genetic testing when clinical guidance, family history or genetic knowledge changes.
To ask the Secretary of State for Health and Social Care, what mechanisms are in place to identify and reassess patients previously considered ineligible for hereditary cancer genetic testing when clinical guidance, family history or genetic knowledge changes.
NHS England is responsible for commissioning the NHS Genomic Medicine Service (GMS) in England. The NHS GMS delivers genomic testing for over 7,000 rare diseases and 200 cancers. Genomic testing for a range of inherited cancers is available on the National Genomic Test Directory (the Test Directory).
Individuals should discuss with their healthcare professional whether genomic testing is appropriate for them, including in circumstances where information about their family history has changed. Their healthcare professional will then review the latest clinical guidance and make a decision whether to refer the individual either directly or via an NHS Clinical Genomics Service or other relevant clinical speciality for genomic testing following clinical review of their and their family’s medical history if known, and the Test Directory eligibility criteria.
A robust and evidence-based process and policy is in place to routinely review the Test Directory and ensure that genomic testing continues to reflect the latest scientific evidence and is available for all patients for whom it would be of clinical benefit, while delivering value for money for the National Health Service.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to reduce barriers to clinical research into psychedelic therapies involving Schedule 1 controlled drugs.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to reduce barriers to clinical research into psychedelic therapies involving Schedule 1 controlled drugs.
I refer the Hon. Member to the answer provided on 19 October in response to Question 31239.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 13 October 2026 to Question 34398 on ME/CFS: Health Services, what assessment her Department has made of the effectiveness of its efforts to promote the e-learning modules; and what further steps it plans to...
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 13 October 2026 to Question 34398 on ME/CFS: Health Services, what assessment her Department has made of the effectiveness of its efforts to promote the e-learning modules; and what further steps it plans to...
As of October 2026, 2,133 people have accessed any or all of the e-learning modules. Of those, 1,064 people have completed at least one module.
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): the final delivery plan committed to promoting the e-learning through a range of channels such as the Royal College of General Practitioners, the Chartered Society of Physiotherapy and the Royal College of Occupational Therapists. The modules were also added to the National Institute for Health and Care Excellence tools and resources page for ME/CFS. The Department is continuing to explore further possible avenues for promotion.
To ask the Secretary of State for Health and Social Care, pursuant to the answer of 13 October 2026 to Question 34398 on ME/CFS: Health Services, how many of the people who accessed the e-learning modules have completed them.
To ask the Secretary of State for Health and Social Care, pursuant to the answer of 13 October 2026 to Question 34398 on ME/CFS: Health Services, how many of the people who accessed the e-learning modules have completed them.
As of October 2026, 2,133 people have accessed any or all of the e-learning modules. Of those, 1,064 people have completed at least one module.
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): the final delivery plan committed to promoting the e-learning through a range of channels such as the Royal College of General Practitioners, the Chartered Society of Physiotherapy and the Royal College of Occupational Therapists. The modules were also added to the National Institute for Health and Care Excellence tools and resources page for ME/CFS. The Department is continuing to explore further possible avenues for promotion.